Guggenheim maintains Buy on Universal Health Services, cuts target to $195
Guggenheim analyst Jason Cassorla kept a Buy rating on Universal Health Services (NYSE: UHS) but lowered the price target to $195 from $211, reflecting a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Guggenheim analyst Jason Cassorla maintained a Buy rating on Universal Health Services (NYSE: UHS) while reducing the price target to $195 from the previous $211. The revised target reflects a recalibration of the stock's valuation potential despite the continued positive outlook.
Rating and Price Target Adjustment
The decision to lower the price target comes as the firm reassesses Universal Health Services' market position. The Buy rating indicates confidence in the company's long-term performance, even as the near-term price expectations are tempered.
Key Details
| Metric | Value |
|---|---|
| Rating | Buy |
| New Price Target | $195 |
| Previous Price Target | $211 |
Universal Health Services continues to be viewed favorably by Guggenheim, with the adjusted price target suggesting a more conservative approach to its near-term upside.
What specific factors led to the recalibration of Universal Health Services' valuation potential?
How might the revised price target influence investor sentiment in the healthcare sector?
What are the expected near-term challenges for Universal Health Services despite the Buy rating?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
